Seed Health to Present New Data on 'DS-01® Daily Synbiotic' for Antibiotic Recovery and IBS at Digestive Disease Week 2024

Seed Health is set to unveil new clinical findings on its innovative product, DS-01® Daily Synbiotic, at the forthcoming 2024 Digestive Disease Week® (DDW) conference. This 24-strain probiotic and prebiotic has been the focus of two significant randomized, double-blind, placebo-controlled clinical trials. These studies examine DS-01®'s efficacy in aiding recovery during and after antibiotic use, as well as its impact on patients suffering from irritable bowel syndrome (IBS). The results highlight Seed Health's commitment to translating advanced microbiome science into practical health solutions for consumers.

Dr. Zain Kassam, Chief Medical Officer at Seed Health, emphasized the unique formulation of DS-01®, designed to optimize genomic diversity and set a new benchmark for probiotics. He noted that the latest clinical data reveal the extended potential health benefits of DS-01®, expanding its applications and challenging the misconception that all probiotics are equal.

Chief Scientific Officer Dirk Gevers, Ph.D., highlighted the rigorous biopharmaceutical approach that Seed Health employs. He noted that the research presented at DDW showcases advanced biomarker analysis and microbiome sequencing, especially in the context of antibiotic recovery and IBS treatment.

The first presentation, titled "Effects of a multi-species synbiotic on microbiome resilience and gastrointestinal barrier function after antibiotics," investigated the impact of DS-01® on patients during and post-antibiotic therapy. The study found that DS-01® significantly improved gut barrier integrity, with a 25% enhancement at Day 7 and a 49% improvement by Day 91. Additionally, DS-01® helped restore baseline microbial diversity and enriched both synbiotic and endogenous beneficial bacteria.

The second presentation, "A multi-species synbiotic (DS-01) alleviates irritable bowel syndrome symptoms while boosting synbiotic consortium," evaluated DS-01®'s effects on IBS patients. Results showed a notable and clinically significant reduction in abdominal pain among IBS sufferers. The study also observed an increase in beneficial bacteria and a significant rise in serotonin levels in participants with mixed IBS (IBS-M), suggesting a potential mechanism of action.

Seed Health, a pioneering company in microbiome science, focuses on developing probiotic and living medicine innovations that benefit both human and planetary health. The company was established to harness the potential of the microbiome, facilitating the translation of groundbreaking science into a wide range of health applications. Seed Health's consumer products are marketed under the Seed® brand, acclaimed for its scientifically validated probiotic innovations, including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily Synbiotic. Their product pipeline addresses various health needs, from gastrointestinal and digestive health to women’s health, skin care, pediatrics, brain health, metabolic function, and healthy aging. Furthermore, Seed Health's environmental research arm, SeedLabs, is dedicated to developing bacterial interventions aimed at enhancing biodiversity and restoring ecosystems affected by human activities.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!